Technology
Revolutionizing ADCs with precision and innovation
Breakthrough
Linker Technology
Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.
Unique design features are incorporated in the linker technology to reduce off-target effects and improve payload delivery to tumors.
Innovative
Payloads
Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.
Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development
at Baylink.
Addressing
Key Challenges
Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance.
This drives the next wave
of precision ADCs.
News
Get the latest updates from us
Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit
PALO ALTO, CA, UNITED STATES, August 13, 2025 -- Baylink Biosciences, a biotechnology ...
Dec 5, 2025
149
Baylink Presents New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
PALO ALTO, Calif., April 25, 2025 -- Baylink Biosciences presented data from its Antibody Drug Conjugate portfolio ...
Apr 25, 2025
539
Baylink To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
PALO ALTO, Calif., April 15, 2025 -- Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at ...
Apr 15, 2025
362